Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology

Lightspeed Microscopy,Inc.在A轮融资中筹集400万美元,计划革新病理学

2021-06-16 06:00:36 BioSpace

本文共1406个字,阅读需4分钟

SEATTLE, June 15, 2021 /PRNewswire/ -- Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 million in a Series A financing round.  The round was led by Dynamk Capital and is expected to close with participation from additional investors by mid-July. The new funding will be used to commercialize and scale Lightspeed's microscopy platform. Lightspeed's technology combines novel chemistry, patented open-top light-sheet microscopy, and cloud-based AI data analysis to non-destructively image large tissues in 3D at a sub-cellular resolution. The platform is a complete solution that includes tissue labelling, tissue clearing, high-throughput imaging, cloud-based processing, and 3D digital analysis. Together, these technologies greatly improve the accuracy and speed of preclinical testing while creating compelling new insights. "The questions being asked in Pharma R&D departments are increasingly complex and often cannot be answered with traditional 2D pathology," said Nicholas Reder, MD, MPH, CEO of Lightspeed Microscopy. "We provide our Pharma customers with novel biological insights using our patented 3D open-top light-sheet microscope combined with AI analysis. As we prepare for our next stage in growth, we are excited to partner with Dynamk Capital, a firm with extensive experience and a strong track record of helping promising life sciences tools companies reach their potential to transform the industry." "Traditional 2D pathology used in product development and diagnostics is a laborious and slow process" said Dr. Gustavo Mahler, General Partner at Dynamk Capital. "By integrating multiple distinct disciplines, Lightspeed is positioned to both accelerate pathology in existing workflows and unlock entirely new insights by greatly increasing access and ease of 3D pathology. Lightspeed and its leadership are well positioned to lead the 3D pathology space." About Lightspeed Microscopy Lightspeed Microscopy Inc. reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology. Lightspeed, spun-out of the University of Washington and co-founded by Nick Reder in 2018, is based in Seattle, WA. For more information, please visit www.lightspeedbio.com About Dynamk Capital Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials. Dynamk's investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of biotherapeutics, including cell & gene therapies, and vaccines. The Dynamk team of experienced life science entrepreneurs, investors, advisors, and subject matter experts provides capital and strategic advice to entrepreneurs commercializing innovative life science technologies. Please visit dynamk.vc for more information. Media Contact: info@lightspeedmicro.com View original content to download multimedia:http://www.prnewswire.com/news-releases/lightspeed-microscopy-inc-raises-4m-in-series-a-financing-round-with-plans-to-revolutionize-pathology-301313016.html SOURCE Lightspeed Microscopy, Inc.
西雅图2021年6月15日电/PRNewswire/--端到端3D病理学平台Lightspeed Microscopy,Inc.今天宣布,它已在a轮融资中筹集到400万美元。这轮融资由Dynamk Capital牵头,预计7月中旬将有更多投资者参与。 新的资金将用于LightSpeed的显微镜平台的商业化和规模化。LightSpeed的技术结合了新颖的化学、专利的开顶光片显微镜和基于云的AI数据分析,以亚细胞分辨率对大型组织进行3D无损成像。该平台是一个完整的解决方案,包括组织标记、组织清除、高通量成像、基于云的处理和3D数字分析。这些技术结合在一起,极大地提高了临床前测试的准确性和速度,同时创造了令人信服的新见解。 Lightspeed Microscopy公司首席执行官、医学博士、公共卫生硕士尼古拉斯·雷德说:“制药研发部门提出的问题越来越复杂,而且通常无法用传统的二维病理学方法来回答。“我们利用我们的专利3D开顶光片显微镜结合人工智能分析,为我们的制药客户提供新颖的生物洞察力。在我们为下一个增长阶段做准备的时候,我们很高兴能与Dynamk Capital公司合作,Dynamk Capital公司在帮助有前途的生命科学工具公司发挥其改造行业的潜力方面有着丰富的经验和良好的记录。” Dynamk Capital的普通合伙人Gustavo Mahler博士说:“在产品开发和诊断中使用的传统2D病理学是一个费力而缓慢的过程。”通过整合多个不同的学科,Lightspeed定位于既加速现有工作流程中的病理学,又通过极大地增加3D病理学的访问和易用性来打开全新的洞察力。Lightspeed及其领导机构完全定位于领导3D病理学领域。“ 关于光速显微镜 Lightspeed Microscopy Inc.通过提供全堆叠解决方案,以亚细胞分辨率在3D中对大组织进行无损成像,重新成像病理学。其新颖的化学,专利的高通量光片显微镜,以及基于云的AI分析软件为病理学增加了一个新的维度。Lightspeed是从华盛顿大学分离出来的,由Nick Reder于2018年联合创立,总部位于华盛顿州西雅图。 欲了解更多信息,请访问www.lightspeedbio.com 关于Dynamk Capital Dynamk Capital是一家专注于生命科学产业的成长型股权和风险投资公司。Dynamk公司的投资战略是确定那些开发颠覆性技术、工具和服务的公司,这些技术、工具和服务能够使生物治疗药物(包括细胞和基因治疗和疫苗)的发现、开发和制造成为完整的生物制药连续体。由经验丰富的生命科学企业家、投资者、顾问和主题专家组成的Dynamk团队为将创新生命科学技术商业化的企业家提供资本和战略建议。有关更多信息,请访问dynamk.vc。 媒体联系人: info@lightspeedmicro.com 查看原始内容下载多媒体:http://www.prnewswire.com/news-releases/lightspeed-microscopy-inc-raises-4m-in-series-a-financing-round-with-plans-to-revolutionize-pathology-301313016.html SOURCE Lightspeed Microscopy公司。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文